1 A Pharma GmbH
1 A Pharma GmbH, headquartered in Germany, is a prominent player in the pharmaceutical industry, specialising in the development and distribution of high-quality generic medicines. Founded in 2003, the company has established a strong presence across Europe, focusing on key operational regions that include Germany and other EU markets. With a diverse portfolio of products, 1 A Pharma is renowned for its commitment to quality and affordability, offering a wide range of therapeutic areas such as pain management, cardiovascular health, and infectious diseases. The company’s unique approach combines rigorous quality control with innovative manufacturing processes, ensuring that their products meet the highest standards. Recognised for its market position, 1 A Pharma has achieved significant milestones, including numerous product launches and partnerships that enhance its competitive edge. As a trusted name in the pharmaceutical sector, 1 A Pharma continues to contribute to improved healthcare outcomes across its operational regions.
DitchCarbon Score
How does 1 A Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
1 A Pharma GmbH's score of 94 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
1 A Pharma GmbH, headquartered in Germany, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Novartis AG, from which it inherits climate commitments and initiatives. 1 A Pharma GmbH's climate strategy is influenced by Novartis AG's sustainability efforts, which include participation in various initiatives such as the Science Based Targets initiative (SBTi), CDP, and RE100. These initiatives aim to drive significant reductions in greenhouse gas emissions across their operations. While specific reduction targets for 1 A Pharma GmbH are not detailed, the overarching commitments from Novartis AG suggest a strong focus on sustainability and climate action. As a current subsidiary, 1 A Pharma GmbH aligns its climate efforts with those of Novartis AG, which is actively working towards ambitious climate goals. In summary, while 1 A Pharma GmbH does not provide specific emissions data or reduction targets, it is committed to climate initiatives through its association with Novartis AG, reflecting a broader industry trend towards sustainability and emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
1 A Pharma GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
